Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces the amount of acid produced in the stomach.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
## Adult Dosing
* **Erosive esophagitis:** 40 mg orally once daily for up to 8 weeks. A subsequent 8-week course may be initiated in patients with non-healing esophageal lesions.
* **Maintenance of healing:** 40 mg orally once daily.
* **Pathological hypersecretory conditions:** Starting dose is typically 40 mg orally twice daily. Doses may be increased as clinically indicated. Doses up to 240 mg daily have been administered intravenously.
## Pediatric Dosing
* **Erosive esophagitis (5 to 16 years):** 20 mg to 40 mg orally once daily for up to 8 weeks.
* **GERD symptoms (2 to 16 years):** 20 mg to 40 mg orally once daily for up to 8 weeks.
* **Erosive esophagitis (less than 5 years):** Safety and efficacy not established. Data is limited; use should be guided by specialist consensus and may involve doses of 0.4-1.2 mg/kg/day divided BID or QD, not to exceed 40 mg/day.
## Dose Adjustments
* **Hepatic impairment:** Maximum daily dose of 40 mg.
* **Renal impairment:** No dose adjustment generally needed, but caution is advised.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, vomiting, dizziness, flatulence.
* **Serious:** Clostridium difficile-associated diarrhea, bone fracture (hip, wrist, spine), hypomagnesemia (can be severe, may lead to neuromuscular or cardiac disturbances), vitamin B12 deficiency (long-term use), fundic gland polyps.
## Key Drug Interactions
* **Drugs requiring gastric acid for absorption:** Ketoconazole, itraconazole, iron salts, vitamin B12. Pantoprazole can decrease absorption.
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity. Consider PPI discontinuation during methotrexate treatment.
* **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. Consider potential for altered metabolism of drugs like clopidogrel, though clinical significance is debated.
* **Atazanavir and Nelfinavir:** PPIs can decrease the absorption of these HIV medications.
## Monitoring
* Electrolytes (especially magnesium) with prolonged therapy or in patients on concomitant diuretics.
* Bone mineral density in patients at risk for osteoporosis.
* Consider B12 levels in patients on long-term therapy.
* Monitor for signs and symptoms of C. difficile infection.
## Clinical Pearls
* Administer 30 minutes to 1 hour before a meal.
* For delayed-release tablets, instruct patients to swallow whole and not to crush, chew, or split them.
* IV formulation is available for patients unable to take oral medication.
* Long-term PPI use is associated with increased risk of fractures, C. difficile infection, and hypomagnesemia. Consider the shortest duration of therapy needed.
---
*Disclaimer: This information is intended for clinical use and does not substitute for professional medical judgment. Always verify current prescribing information with the official product monograph and relevant guidelines.*
